Nature Reviews Rheumatology

Article	Citations
Inflammatory arthritis affects men’s fertility	559
SLC26A2 deficiency, matrix stiffness and mechanotransduction linked in osteoporosis	427
Bimekizumab effective across the axSpA spectrum	371
No benefit from adding MTX to ustekinumab	332
Targeting articular Mmp13 in OA	302
Low-dose rituximab can go even lower	284
Genome-wide mutagenesis reported in systemic sclerosis	268
Rheumatic diseases on the rise	241
A role for TGFβ and EBV in MIS-C pathogenesis	221
COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations	191
Biological and clinical roles of IL-18 in inflammatory diseases	181
New drug formulation reduces bone loss	180
FOXP3 splice variant is associated with autoimmune disease	170
Towards better management of sterile bone inflammation	163
Use of platelet-rich plasma for knee OA not supported by RCT results	156
MIS-C: myths have been debunked, but mysteries remain	155
Inflammation across tissues: can shared cell biology help design smarter trials?	149
Urchin-like nanoparticles for miRNA therapy of OA	148
2021 ACR guideline for JIA reflects changes in practice	136
The 2022 ACR vaccination guideline: a call-to-action	135
The value of comparative efficacy studies in informing rheumatology guidelines	125
Imbalance of threat and soothing systems in fibromyalgia: rephrasing an established mechanistic model?	115
To choose or not? The value of discrete-choice experiments in rheumatology	114
Down syndrome: insights into autoimmune mechanisms	108
Ageing stem cells hold the key to age-related bone degeneration	107

Appraising the evolving landscape of protease inhibition in osteoarthritis	106
Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	100
Co-trimoxazole reduces mortality in anti-MDA5-DM	99
Which NSAIDs are best for OA treatment?	99
Low-dose glucocorticoids benefit seniors with RA	98
S100A4 inhibition targets fibrosis in SSc	90
Calprotectin tracks tocilizumab-treated RA	89
Publisher Correction: Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician	88
Biologics in rheumatoid arthritis: a lifetime treatment or possibility of drug holidays?	88
Wnt-induced IGF1 drives OA	88
Author Correction: Proposals for the rheumatological use of JAK inhibitors	85
Guiding ILD management in systemic autoimmune rheumatic diseases	84
A direct link between SARS-CoV-2 and bone loss	82
Fumarate drives interferon release in systemic sclerosis monocytes	79
Rheumatic diseases and metabolism: where centre and periphery meet	79
Low back pain is a growing concern	78
Sexual dimorphism in the prevalence, manifestation and outcomes of axial spondyloarthritis	77
Rheumatology in the digital health era: status quo and quo vadis?	76
Distinct mucosal endotypes as initiators and drivers of rheumatoid arthritis	76
sCD13 role in arthritis mediated via bradykinin receptor	74
Antibiotics keep rheumatic heart disease at bay	73
Targeting the IVD clock to halt degeneration	71
Erosive cargo from synovial fibroblasts	71
Which DMARD for ICI-associated arthritis?	68
Macrophage-coated nanocarriers for gouty arthritis	67
Publisher Correction: Recent advances in the diagnosis and management of neuropsychiatric lupus	67
ERAP1 and the return of the UPR in ankylosing spondylitis	66
Chimeric receptors broaden the therapeutic landscape for autoimmune disease	65
CAR T cells induce drug-free SLE remission	64
PGE2 receptor antagonist has potential to treat osteoarthritis	64
Insights into IVDD pathogenesis in 2024	64
A path towards personalized medicine for autoinflammatory and related diseases	63
International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	62
Janus kinase-targeting therapies in rheumatology: a mechanisms-based approach	61
Antibodies induce fibromyalgia symptoms	61
Blocking CDK7 attenuates inflammatory arthritis	60
PPIs linked to increased risk of knee replacement	59
TASL has a key role in SLE	57
RA risk from occupational inhalation	57
Two sides of management recommendations for psoriatic arthritis	56
Improving the design of RCTs in non-radiographic axial spondyloarthritis	55
All fibroblasts are equal, but some are more equal than others	54
Repolarizing macrophages using antagomirs	53
Is air pollution linked with poor response to biologics?	53
New hope for B cell-targeting therapy in pSS	52
A critical view of WHO guidelines on management of low back pain	49
A leading role for interferon as a treatment target in Sjögren syndrome	49
Pan American League of Associations for Rheumatology recommendations for the management of axial spondyloarthritis	47
New developments in electronic health record analysis	47
New refinements aim to optimize articular cartilage tissue engineering	46

Profiling joint tissues at single-cell resolution: advances and insights	45
Publisher Correction: The impact of COVID-19 on rare and complex connective tissue diseases: the experience of ERN ReCONNET	44
Author Correction: Glycobiology of rheumatic diseases	44
Piezo1 induces new bone formation in AS	44
Author Correction: International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening: an International Myositis Assessment and Clinical Studies Group (IMACS) initiative	43
Clarity for the language of race, ethnicity and genetic ancestry in rheumatology	41
AhR promotes suppressor cell function in Sjögren syndrome	40
Pathogenic antibodies target stromal antigens in RA	39
Sex- and gender-based personalized medicine in rheumatology	39
l-arginine inhibits arthritis and bone loss by reprogramming osteoclast metabolism	39
APOE in fat pad and synovium contributes to knee OA	39
Treg cell-inducing nanoparticles show promise for treating OA	37
CXCL5 effective in mouse model of SLE	37
Are DNA–HLA class II interactions the missing link in SLE?	36
Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases	36
Critical appraisal of serum urate targets in the management of gout	36
IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting	36
Stromal cells implicated in RA genetic risk	34
Imaging for prediction of RA development	33
HLA autoimmunity risk alleles influence T cell receptor sequences	32
B cell X-chromosome inactivation is faulty in SLE	32
New OA risk factors and drug targets revealed	32
BiTE therapy for rheumatic diseases	31
Shifting the SLE management paradigm: challenges and implications	31
FABP4 exacerbates RA	30
Post-transcriptional checkpoints in autoimmunity	30
PDGFR signalling implicated in anti-resorptive effects of sclerostin blockade	27
Mechanisms and clinical implications of intervertebral disc calcification	25
Location-specific treatment of chronic inflammatory joint disease	25
Guselkumab effective through 2 years in PsA trial	25
Interferon disrupts immune and tissue homeostasis in SLE via CXCL13	25
COVID-19 linked to rise in anti-MDA5 autoimmunity	24
Detachment promotes RA synovial fibroblast survival and invasiveness	23
PLG nanoparticles target inflammatory monocytes in SSc	23
Multi-omics reveals distinct MPA subtypes	22
Adropin inhibits fibrosis in SSc	22
Complement therapeutics are coming of age in rheumatology	21
Notch signalling mediates OA pain in mice	21
Busting the myth of methotrexate chronic hepatotoxicity	20
Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis	20
State-of-the-art evidence in the treatment of systemic sclerosis	20
The potential contribution of in silico studies to improved treatment of osteoarthritis	19
Reply to: Combining TNF blockade with immune checkpoint inhibitors in patients with cancer	19
Citrulline immunity in RA: CD8+ T cells enter the scene	19
How the COVID-19 pandemic has affected rheumatology research	18
Joint distraction for osteoarthritis: clinical evidence and molecular mechanisms	17
Single-cell RNA sequencing sheds light on cell-type specific gene expression in immune cells	17
Treatment of non-systemic juvenile idiopathic arthritis	16
Update on the pathophysiology and treatment of primary Sjögren syndrome	15
Mechanisms of joint destruction in rheumatoid arthritis — immune cell–fibroblast–bone interactions	15
Primary care rheumatology: towards sustainable development in health	15
Shedding light onto the immunometabolic effects of glucocorticoids	14
Undiagnosed axSpA is prevalent in IBD	14
Lupus ABC spearheading a new era of collaboration to advance lupus drug development	14
Low-frequency and rare genetic variants associated with rheumatoid arthritis risk	14
No benefit to intensive urate lowering in gout	14
Bone-modifying drugs slow OA progression	14
The immune health metric as an indicator of health and disease	14
UNC93B1 variants promote SLE via TLR activation	14
Advances in viscosupplementation and tribosupplementation for early-stage osteoarthritis therapy	14
Cellular metabolic adaptations in rheumatoid arthritis and their therapeutic implications	13
The PU.1– IL-9 axis in TH9 cells promotes RA	13
Glycosylation switch in synovial fibroblasts promotes ECM degradation	13
Interleukin-2 and regulatory T cells in rheumatic diseases	13
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?	13
Combination therapy for Behçet uveitis	13
Reversal of inflammatory priming prevents arthritic flares	12
Paediatric glucocorticoid toxicity index: new possibilities in assessment	12
T cell differentiation in Sjögren syndrome is regulated by TOX	12
Reply to: Is classifying SSc-ILD drugs as either immunosuppressive or anti-fibrotic misleading?	12
New guide calls for interdisciplinary approach to TMJ arthritis symptoms	12
The role of the immune system in osteoarthritis: mechanisms, challenges and future directions	12
Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy	11
Evidence-Based Guideline for the management of osteoporosis in men	11
Advances in the calculation of minimal important change estimates for patient-reported outcome measures	11
Current challenges in understanding the epidemiology of calcium pyrophosphate crystal deposition	11
Disease stratification in GCA and PMR: state of the art and future perspectives	11
The pathogenesis of gout: molecular insights from genetic, epigenomic and transcriptomic studies	10
Novel TLR7 variant causes lupus	10
Pregnancy outcomes improving in axSpA	10

Combining TNF blockade with immune checkpoint inhibitors in patients with cancer

10